Q-omics provides the consensus-scored NOL3 profile across patient tissues and cancer cell-line models. NOL3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NOL3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NOL3 protein abundance shows 16,949 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, KIRC, and GBM as cancer lineages where NOL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOL3 survival associations across molecular data types. NOL3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOL3 RNA expression–survival associations across cancer types. High NOL3 expression shows unfavorable associations in COAD, CESC, BLCA, LGG, LIHC and KICH. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for NOL3 RNA expression.
This table summarizes NOL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NOL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOL3 shows higher tumor expression in KIRC, KIRP, COAD, LIHC, LUAD and READ. The KIRC box plot shows higher NOL3 RNA expression in tumor versus normal tissue (log2 FC = +3.180, t-test p < 0.001).
This table shows molecular features associated with NOL3 in patient tissues and cancer cell lines. In patient samples, NOL3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NOL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
